Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
- Trial name
- ROCSTAR (NCT07175038)
- Testing
- ROC-101
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AllRock Bio, Inc.
Pulmonary Vascular Disease, Pulmonary Artery Hypertension
High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)
The investigators aim to study the effect of SOT in participants with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live >2500m…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT06003244
- Testing
- 6-minute walk distance (6MWD) test, 6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
This is a multicenter, randomized (2:1 oral treprostinil: placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are currently receiving background dual therapy (ambrisentan…
- Trial name
- NCT02999906
- Testing
- Oral Treprostinil
- Sponsor
- United Therapeutics
Pediatric Pulmonary Hypertension
Actigraphy in Pediatric Pulmonary Hypertension
Physical activity is an important factor in understanding how diseases can affect a child. Decreases in physical activity are sometimes the first thing that happens before a child is diagnosed with a disease.
- Trial name
- NCT02909608
- Testing
- No interventions / observations only
- Where
- 2 sites in United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Pulmonary Artery Hypertension
Non-Invasive Measurements of Changes in Pulmonary Artery Pressure in Intensive Care Unit Patients Using Electrical Impedance Tomography - A Feasibility Study
To assess whether changes in electrical impedance - measured using an electrical impedance tomography (EIT) chest belt - can be used to derive changes in pulmonary artery pressure (PAP) in critically ill patients when compared to…
- Trial name
- PAP-EIT (NCT06544148)
- Testing
- Electrical impedance tomography
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Pulmonary Arterial Hypertension
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH).
- Trial name
- NCT00439946
- Testing
- treprostinil, Crono Five ambulatory pump
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument
SYMPHONY Extension is an extension of AC-055-401, a multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to psychometrically validate the PAH-SYMPACT instrument.
- Trial name
- SYMPHONYext (NCT01847014)
- Testing
- Macitentan
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Actelion
Pre-Eclampsia; Complicating Pregnancy, Antiphospholipid Syndrome in Pregnancy
Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure
The primary goal of this observational study is to learn about postpartum pulmonary artery pressure in women who suffered from Preeclampsia and Antiphospholipid Syndrome.
- Conditions
- Pre-Eclampsia; Complicating Pregnancy, Antiphospholipid Syndrome in Pregnancy, Pulmonary Hypertension
- Trial name
- NCT05679206
- Testing
- Echocardiography images, 24-hour ambulatory blood pressure monitoring
- Where
- Switzerland
- Volunteers
- 900 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension
A Mobile Health Intervention in Pulmonary Arterial Hypertension
This study proposes the use of a mobile health intervention (utilizing a smart phone app) to encourage increased exercise in PAH patients.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
- Trial name
- mHealth (NCT03069716)
- Testing
- Smartphone Text Messaging, Fitbit Charge HR
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Vanderbilt University Medical Center
Chronic Obstructive Pulmonary Disease
Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary
The Multi-Ethnic Study of Atherosclerosis (MESA) - Chronic Obstructive Pulmonary Disease (COPD) Study aims to characterize the pulmonary vascular changes and their biology in early COPD using imaging, gene expression profiling…
- Trial name
- MESA-COPD (NCT01397721)
- Where
- 4 sites in United States
- Volunteers
- 359 people
- Sponsor
- Columbia University
Pulmonary Hypertension
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
Pulmonary Arterial Hypertension (PAH) is a severe progressive disease with a high mortality. Although several drugs are available for the treatment of PAH none offer a cure, therefore there is still a high medical need for new…
- Trial name
- PATENT PLUS (NCT01179334)
- Testing
- Riociguat (Adempas, BAY63-2521), Sildenafil
- Where
- 25 sites in United States, Austria and 7 more
- Volunteers
- 18 people
- Sponsor
- Bayer
Pulmonary Hypertension
Fractal Analysis of the Pulmonary Arterial Tree in Pulmonary Hypertension
The investigators propose to confirm that normotensive and hypertensive pulmonary arteries are fractal, as well as define if the FD correlates to disease severity when compared to available data such as six-minute walk and right…
- Trial name
- NCT01135706
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ohio State University
Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
What is this study about? This study will test whether adding sotatercept to usual medicines for pulmonary arterial hypertension (PAH) can help adults who have PAH due to unrepaired congenital heart defects (atrial or ventricular…
- Trial name
- SuMILE (NCT07356778)
- Testing
- Sotatercept, vasodilator-based PAH therapy
- Where
- 10 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Kazuya Hosokawa
Pulmonary Hypertension, Pulmonary Arterial Hypertension
MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension
The investigators will investigate the interrelationship of macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease
- Trial name
- NCT02858791
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Pulmonary Hypertension
Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension
In a group of patients with PAH treated with treprostinil, the current study aims to investigate the effect of treatment on RV structure and function; and correlate changes in RV structure and function with: World Health…
- Trial name
- NCT03835676
- Testing
- Treprostinil
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Magdi H. Yacoub
Pulmonary Arterial Hypertension
RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists
This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021.
- Trial name
- RAMPHA (NCT05600218)
- Testing
- No intervention - Observational study
- Where
- 10 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Costa del Sol
Pulmonary Arterial Hypertension
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin.
- Trial name
- NCT06554301
- Testing
- empagliflozin in treatment pulmonary aerterial hypertension
- Where
- China
- Volunteers
- 72 people
- Sponsor
- China National Center for Cardiovascular Diseases
Idiopathic Pulmonary Arterial Hypertension
Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial
The goal of this research is to investigate the effectiveness of exercise administered via immersive virtual reality in patients with pulmonary hypertension, thereby contributing to the existing literature on this subject.
- Trial name
- NCT07558460
- Testing
- Virtual Reality Group
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Istanbul University - Cerrahpasa
Pulmonary Arterial Hypertension (PAH), Lung Fibrosis Interstitial
PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.
The PROMPTLY study is a proof-of-concept research project evaluating the efficacy of XHALIP, an innovative inhalable formulation of Imatinib, in treating pulmonary arterial hypertension (PAH) and post-inflammatory fibrosing lung…
- Trial name
- PROMPTLY (NCT06917196)
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Portopulmonary Hypertension, Pulmonary Arterial Hypertension
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
This was a multicenter, prospective, observational, open-label study. Patients meeting inclusion/exclusion criteria received treatment with treprostinil as recommended by their treating physicians and were followed according to…
- Conditions
- Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Trial name
- NCT01028651
- Testing
- Treprostinil
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- United Therapeutics